Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

CRF: Circulating recombinant form; NNRTI: Non-nucleoside reverse-transcriptase inhibitor; NRTI: Nucleos(t)ide analog reverse-transcriptase inhibitor. Eight nucleos(t)ide analog reverse ...

Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational ...

自从人类免疫缺陷病毒 (HIV)于20世纪80年代初初次被发现，迄今近半个世纪已经过去了，人类仍然未能获得一种有效的艾滋病 疫苗。目前全球的疫苗学家们面临的最大挑战之一就是开发有效的艾滋病疫苗。

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Launched in April 2024 as part of Secretary of Education Miguel Cardona ’s Raise the Bar initiative, the Postsecondary Success Recognition Program highlights institutions that demonstrate exceptional ...

It is an ester-derived prodrug that is converted in vivo by serum and tissue esterases to tenofovir, an acyclic nucleoside phosphonate (nucleotide) that inhibits HIV reverse transcriptase.

The four main classes, which most people are treated with, target one of three viral proteins which control HIV’s lifecycle: reverse transcriptase, integrase and protease. Historically, most people ...

The following is a summary of “High-density lipoprotein anti-inflammatory capacity and acute kidney injury after cardiac and ...

For this purpose, anti-HIV drugs target essential viral proteins in the replication cycle of HIV, mostly the viral reverse transcriptase and protease. Unfortunately, HIV is highly variable and ...